pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Wegovy · news · pharmadog
← back to Wegovy
News mentioning Wegovy
133
stories
Aug 6, 26
Actimed gets back rights to wasting disease drug, ending $126M deal with Faraday
fiercebiotech
Aug 5, 26
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
biospace
Aug 5, 26
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
Aug 5, 26
Lilly climbs, Novo falls as obesity drug battle intensifies
biopharma dive
Aug 5, 26
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
Aug 5, 26
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
Aug 5, 26
‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
fiercebiotech
Aug 5, 26
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
Aug 4, 26
Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat
biospace
Jul 31, 26
Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
biospace
Jul 31, 26
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
Jul 29, 26
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
biopharma dive
Jul 29, 26
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
biospace
Jul 29, 26
Novo Nordisk fails to dismiss lawsuit over CagriSema readout
fiercebiotech
Jul 28, 26
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
fiercebiotech
Jul 24, 26
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
Jul 23, 26
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
Jul 23, 26
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
Jul 23, 26
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
Jul 21, 26
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
biospace
Jul 21, 26
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
biopharma dive
Jul 21, 26
STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
stat
Jul 21, 26
STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
stat
Jul 20, 26
STAT+: Pharmalittle: We’re reading about a telehealth firm and patient safety, PBMs overcharging, and more
stat
Jul 20, 26
STAT+: Telemedicine company touted by Novo Nordisk stressed profits over patient safety, ex-workers say
stat
Jul 17, 26
Compounders maintain a firm grip on the GLP-1 market
biopharma dive
Jul 15, 26
STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more
stat
Jul 9, 26
Opinion: Who benefits from classifying obesity as a disease?
stat
Jul 7, 26
Kailera says obesity pill succeeds in late-stage trial in China
biopharma dive
Jul 7, 26
Ebola outbreak exposes a fractured outbreak response system
stat
← prev
page 3 of 5
next →
